A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Prior treatment

• Have a prior or planned surgical treatment for obesity
• Have any of the following cardiovascular conditions within three months prior to screening:
  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure
• Have taken any medications or alternative remedies for weight loss within three months prior to screening

Other illness

• Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma

Lab values

• Have used insulin to control blood glucose within the past year (short-term use allowed)
• Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening
  • If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and/or thiazolidinediones (TZD), they are permitted to participate in the study

• Have type 2 diabetes
• Have HbA1c ≥7.5% to ≤10.5% at screening
• Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening
• Have had a stable body weight for the three months prior to screening
• On stable treatment dose of one of the following incretins for at least three months prior to screening:
  • Injectable semaglutide (1 and 2 milligram (mg))
  • Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)